Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
暂无分享,去创建一个
Pär Stattin | Ove Andrén | Jennifer R. Rider | P. Stattin | P. Wiklund | J. Hugosson | O. Andrén | Jonas Hugosson | Peter Wiklund | Jennifer R Rider | F. Sandin | Fredrik Sandin
[1] A. Partin,et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Holmberg,et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 , 2007, Scandinavian journal of urology and nephrology.
[3] D. Chan,et al. Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .
[4] Hans Garmo,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.
[5] M. Menon,et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. , 2004, The Journal of urology.
[6] Dirk F Moore,et al. Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.
[7] Pär Stattin,et al. Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study , 2010, Journal of the National Cancer Institute.
[8] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[9] Theodore L. DeWeese,et al. Localized Prostate Cancer , 2007 .
[10] L. Holmberg,et al. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. , 2011, The Journal of urology.
[11] P. Stattin,et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. , 2013, International journal of epidemiology.
[12] P. Stattin,et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. , 2011, European urology.
[13] F. Montorsi,et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. , 2011, European urology.
[14] Jennifer R. Rider,et al. Temporal trends in cause of death among Swedish and US men with prostate cancer. , 2012, Journal of the National Cancer Institute.
[15] M. Becich,et al. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. , 2008, The Journal of urology.
[16] A. Rademaker,et al. Cigarette smoking and aneuploidy in human sperm , 2001, Molecular reproduction and development.
[17] C. Simone. Re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95. , 2011, European urology.
[18] P. Carroll,et al. 20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .
[19] J. Hugosson,et al. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: A comparative study of official death certificates with a cause of death committee using a standardized algorithm , 2011, Scandinavian journal of urology and nephrology.
[20] A. S. Kibel. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009 .
[21] P. Carter,et al. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting , 2006, Prostate Cancer and Prostatic Diseases.
[22] Paul W Dickman,et al. Natural history of early, localized prostate cancer. , 2004, JAMA.
[23] Katja Fall,et al. Reliability of death certificates in prostate cancer patients , 2008, Scandinavian journal of urology and nephrology.
[24] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[25] Dirk F Moore,et al. Impact of comorbidity on survival among men with localized prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Mohler. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.